Which has higher valuation & earnings, ABVX or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is ABVX or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media favor ABVX or SLS?

In the previous week, Abivax and Abivax both had 6 articles in the media. Abivax's average media sentiment score of 0.62 beat SELLAS Life Sciences Group's score of 0.49 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SLS or CYTK?

In the previous week, Cytokinetics had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Cytokinetics and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.49 beat Cytokinetics' score of 0.43 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer IBRX or SLS?

In the previous week, ImmunityBio had 4 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 10 mentions for ImmunityBio and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.49 beat ImmunityBio's score of 0.32 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, SLS or NUVL?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is SLS or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -47.12% -42.63% Nuvalent N/A -40.11% -35.43%

Does the media refer more to SLS or NUVL?

In the previous week, Nuvalent had 4 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 10 mentions for Nuvalent and 6 mentions for SELLAS Life Sciences Group. Nuvalent's average media sentiment score of 0.52 beat SELLAS Life Sciences Group's score of 0.49 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SELLAS Life Sciences Group (SLS) Competitors

$12.62 -0.14 (-1.10%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$12.52 -0.09 (-0.75%)

As of 07/13/2026 07:59 PM Eastern

Compare

SLS vs. ABVX, KRYS, CYTK, IBRX, and NUVL

Should you buy SELLAS Life Sciences Group stock or one of its competitors? MarketBeat compares SELLAS Life Sciences Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SELLAS Life Sciences Group include Abivax (ABVX), Krystal Biotech (KRYS), Cytokinetics (CYTK), ImmunityBio (IBRX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does SELLAS Life Sciences Group compare to Abivax?

Abivax (NASDAQ:ABVX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

SELLAS Life Sciences Group's return on equity of -47.12% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

In the previous week, Abivax and Abivax both had 6 articles in the media. Abivax's average media sentiment score of 0.62 beat SELLAS Life Sciences Group's score of 0.49 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abivax presently has a consensus target price of $148.54, indicating a potential upside of 9.24%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential downside of 20.76%. Given Abivax's stronger consensus rating and higher probable upside, equities research analysts plainly believe Abivax is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

47.9% of Abivax shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Abivax has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

Summary

Abivax and SELLAS Life Sciences Group tied by winning 6 of the 12 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Krystal Biotech?

SELLAS Life Sciences Group (NASDAQ:SLS) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Krystal Biotech has a net margin of 53.92% compared to SELLAS Life Sciences Group's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, SELLAS Life Sciences Group had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat SELLAS Life Sciences Group's score of 0.49 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
SELLAS Life Sciences Group	Neutral
Krystal Biotech	Very Positive

Krystal Biotech has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, suggesting a potential downside of 20.76%. Krystal Biotech has a consensus price target of $352.00, suggesting a potential downside of 3.15%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Krystal Biotech is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats SELLAS Life Sciences Group on 13 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Cytokinetics?

SELLAS Life Sciences Group (NASDAQ:SLS) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Cytokinetics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A

In the previous week, Cytokinetics had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Cytokinetics and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.49 beat Cytokinetics' score of 0.43 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Cytokinetics	-784.02%	N/A	-52.86%

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 20.76%. Cytokinetics has a consensus target price of $99.90, suggesting a potential upside of 21.47%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Cytokinetics beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 82.28%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential downside of 20.76%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImmunityBio is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SELLAS Life Sciences Group has lower revenue, but higher earnings than ImmunityBio. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	72.02	-$351.40M	-$0.85	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

In the previous week, ImmunityBio had 4 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 10 mentions for ImmunityBio and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.49 beat ImmunityBio's score of 0.32 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

ImmunityBio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market.

Summary

ImmunityBio beats SELLAS Life Sciences Group on 8 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Nuvalent?

SELLAS Life Sciences Group (NASDAQ:SLS) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential downside of 20.76%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.06%. Given Nuvalent's higher possible upside, analysts plainly believe Nuvalent is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

In the previous week, Nuvalent had 4 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 10 mentions for Nuvalent and 6 mentions for SELLAS Life Sciences Group. Nuvalent's average media sentiment score of 0.52 beat SELLAS Life Sciences Group's score of 0.49 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent's return on equity of -40.11% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Nuvalent	N/A	-40.11%	-35.43%

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Summary

Nuvalent beats SELLAS Life Sciences Group on 9 of the 13 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLS vs. The Competition

Export

Metric	SELLAS Life Sciences Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.51B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-54.87	20.85	27.15	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	27.43	8.49	10.75	6.29
Net Income	-$26.86M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.52%	-3.56%	-2.07%	-1.32%
1 Month Performance	61.17%	6.31%	3.31%	-0.64%
1 Year Performance	537.37%	48.30%	26.35%	19.08%

SELLAS Life Sciences Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLS SELLAS Life Sciences Group	0.7248 of 5 stars	$12.62 -1.1%	$10.00 -20.8%	+585.9%	$2.51B	N/A	N/A	10	Options Volume Gap Down
ABVX Abivax	2.0605 of 5 stars	$143.99 -0.5%	$146.00 +1.4%	+1,544.3%	$11.54B	N/A	N/A	61
KRYS Krystal Biotech	2.6246 of 5 stars	$374.68 -0.1%	$340.56 -9.1%	+145.3%	$11.06B	$389.13M	50.09	210	Positive News Analyst Forecast
CYTK Cytokinetics	2.4822 of 5 stars	$85.57 -1.1%	$100.00 +16.9%	+122.2%	$10.76B	$88.04M	N/A	250
IBRX ImmunityBio	3.1908 of 5 stars	$8.91 -5.6%	$14.20 +59.4%	+177.2%	$9.89B	$113.29M	N/A	590	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. ABVX, KRYS, CYTK, IBRX, and NUVL

How does SELLAS Life Sciences Group compare to Abivax?

Summary

How does SELLAS Life Sciences Group compare to Krystal Biotech?

Summary

How does SELLAS Life Sciences Group compare to Cytokinetics?

Summary

How does SELLAS Life Sciences Group compare to ImmunityBio?

Summary

How does SELLAS Life Sciences Group compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. ABVX, KRYS, CYTK, IBRX, and NUVL

How does SELLAS Life Sciences Group compare to Abivax?

Is ABVX or SLS more profitable?

Does the media favor ABVX or SLS?

Do analysts recommend ABVX or SLS?

Do insiders and institutionals have more ownership in ABVX or SLS?

Which has higher valuation & earnings, ABVX or SLS?

Which has more risk & volatility, ABVX or SLS?

Summary

How does SELLAS Life Sciences Group compare to Krystal Biotech?

Is SLS or KRYS more profitable?

Does the media refer more to SLS or KRYS?

Which has stronger valuation & earnings, SLS or KRYS?

Do institutionals & insiders hold more shares of SLS or KRYS?

Which has more volatility and risk, SLS or KRYS?

Do analysts prefer SLS or KRYS?

Summary

How does SELLAS Life Sciences Group compare to Cytokinetics?

Which has better earnings and valuation, SLS or CYTK?

Does the media refer more to SLS or CYTK?

Is SLS or CYTK more profitable?

Do institutionals and insiders hold more shares of SLS or CYTK?

Which has more volatility & risk, SLS or CYTK?

Do analysts prefer SLS or CYTK?

Summary

How does SELLAS Life Sciences Group compare to ImmunityBio?

Do institutionals and insiders hold more shares of IBRX or SLS?

Do analysts rate IBRX or SLS?

Which has better valuation & earnings, IBRX or SLS?

Does the media prefer IBRX or SLS?

Is IBRX or SLS more profitable?

Which has more volatility & risk, IBRX or SLS?

Summary

How does SELLAS Life Sciences Group compare to Nuvalent?

Do analysts rate SLS or NUVL?

Does the media refer more to SLS or NUVL?

Which has higher earnings & valuation, SLS or NUVL?

Is SLS or NUVL more profitable?

Do insiders and institutionals have more ownership in SLS or NUVL?

Which has more volatility & risk, SLS or NUVL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools